Cannabis-based treatments show promise for CDKL5 Deficiency Disorder, a devastating childhood epilepsy
A review found growing evidence supporting cannabinoid use for CDKL5 Deficiency Disorder (CDD), drawing on proven CBD efficacy in similar syndromes (Dravet, Lennox-Gastaut), anecdotal reports, and an open-label trial showing seizure reduction in CDD specifically.
Quick Facts
What This Study Found
Evidence supports cannabinoids for refractory epilepsies similar to CDD (Dravet, Lennox-Gastaut syndromes). Specific evidence for CDD includes multiple anecdotal reports and an open-label trial showing CBD was associated with significant seizure reduction. This provides the first comprehensive overview of cannabis potential for CDD.
Key Numbers
CBD proven effective in Dravet and Lennox-Gastaut (Phase III RCTs). CDD-specific: multiple anecdotal reports plus open-label trial showing significant seizure reduction with CBD.
How They Did This
Comprehensive review covering cannabis history, mechanism of action, efficacy and safety in epilepsy, and specific evidence for CDKL5 Deficiency Disorder. Includes burden of disease analysis.
Why This Research Matters
CDD is an extremely debilitating genetic disorder with early-onset seizures that rarely respond to existing treatments. Parents are already seeking cannabis products, and this review provides the first organized assessment of the evidence specifically for this condition.
The Bigger Picture
CDKL5 Deficiency Disorder represents the frontier of cannabinoid epilepsy research: conditions too rare for large RCTs but devastating enough that families are not willing to wait for perfect evidence.
What This Study Doesn't Tell Us
CDD-specific evidence is limited to anecdotal reports and one open-label trial. The syndrome is too rare for large RCTs. Extrapolation from Dravet and Lennox-Gastaut may not be fully valid. Mechanism of CBD action in CDD is unknown.
Questions This Raises
- ?Will controlled trials be feasible in this rare population?
- ?What CBD dose is optimal for CDD?
- ?Could genetic characteristics of CDD predict cannabinoid response?
Trust & Context
- Key Stat:
- First comprehensive CDD-cannabis review
- Evidence Grade:
- Rated preliminary because CDD-specific evidence is limited to anecdotal reports and one open-label trial.
- Study Age:
- Published in 2019. Additional CDD-cannabis research may have emerged since.
- Original Title:
- Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.
- Published In:
- Epilepsy research, 151, 31-39 (2019)
- Authors:
- Dale, Tristan, Downs, Jenny, Olson, Heather, Bergin, Ann Marie, Smith, Stephanie, Leonard, Helen
- Database ID:
- RTHC-01997
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can CBD help CDKL5 Deficiency Disorder seizures?
Preliminary evidence is encouraging. CBD has proven effective in similar severe epilepsies (Dravet, Lennox-Gastaut), and an open-label trial showed significant seizure reduction specifically in CDD patients.
What is CDKL5 Deficiency Disorder?
A genetic disorder causing severe early-onset epilepsy, developmental delay, and other neurological problems. Existing treatments are often ineffective, driving families to seek alternatives like cannabis.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01997APA
Dale, Tristan; Downs, Jenny; Olson, Heather; Bergin, Ann Marie; Smith, Stephanie; Leonard, Helen. (2019). Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.. Epilepsy research, 151, 31-39. https://doi.org/10.1016/j.eplepsyres.2019.02.001
MLA
Dale, Tristan, et al. "Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder.." Epilepsy research, 2019. https://doi.org/10.1016/j.eplepsyres.2019.02.001
RethinkTHC
RethinkTHC Research Database. "Cannabis for refractory epilepsy in children: A review focus..." RTHC-01997. Retrieved from https://rethinkthc.com/research/dale-2019-cannabis-for-refractory-epilepsy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.